Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

(2015) Madhusoodanan Mottamal et al.   MOLECULES

Biomarkers of Histone Deacetylase Inhibitor Activity in a Phase 1 Combined-Modality Study with Radiotherapy

(2014) Anne Hansen Ree et al.   PLoS One

Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228

(2013) Shambhunath Choudhary et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

(2013) L. Amiri-Kordestani et al.   CLINICAL CANCER RESEARCH

Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment

(2013) Konstantinos A Papavassiliou et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

SAHA Treatment Reveals the Link between Histone Lysine Acetylation and Proteome in Nonsmall Cell Lung Cancer A549 Cells

(2013) Quan Wu et al.   JOURNAL OF PROTEOME RESEARCH

Combinatorial complexity in chromatin structure and function: revisiting the histone code

(2012) Oliver J Rando   CURRENT OPINION IN GENETICS & DEVELOPMENT

Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma

(2012) Eric J. Sherman et al.   THYROID

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Romidepsin: a novel histone deacetylase inhibitor for cancer

(2011) Erin M Bertino et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide

(2010) Hideki Mizutani et al.   CANCER SCIENCE

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

(2010) Jiahuai Tan et al.   Journal of Hematology & Oncology

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Proteomic Analysis Identifies Protein Targets Responsible for Depsipeptide Sensitivity in Tumor Cells

(2008) Guozhu Chen et al.   JOURNAL OF PROTEOME RESEARCH

Regulation of protein turnover by acetyltransferases and deacetylases

(2007) Karin Sadoul et al.   BIOCHIMIE